Back to Search
Start Over
Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future
- Source :
- Internal Medicine Journal. 48:637-644
- Publication Year :
- 2018
- Publisher :
- Wiley, 2018.
-
Abstract
- Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a lethal disease with a poor 5-year survival. Systemic treatments can be used to control symptoms and prolong life. Cytotoxic chemotherapies are commonly administered, with combination treatments, such as fluorouracil, folinic acid, irinotecan and oxaliplatin (FOLFIRINOX) or nab-paclitaxel and gemcitabine showing the largest clinical benefits. Newer genomic classifications of PDAC may provide a rationale for targeted therapies or immunotherapies, although at present these remain largely experimental. This review discusses the evidence behind the currently used regimens, while introducing the potential future of pancreatic cancer care.
- Subjects :
- Oncology
medicine.medical_specialty
business.industry
FOLFIRINOX
medicine.disease
digestive system diseases
Gemcitabine
Oxaliplatin
Irinotecan
03 medical and health sciences
Folinic acid
0302 clinical medicine
Fluorouracil
030220 oncology & carcinogenesis
Pancreatic cancer
Internal medicine
Internal Medicine
medicine
Adenocarcinoma
030212 general & internal medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 14440903
- Volume :
- 48
- Database :
- OpenAIRE
- Journal :
- Internal Medicine Journal
- Accession number :
- edsair.doi...........dfd3770065cabfc78729ca91e6e41366